BIOMAT Database Logo BIOMAT Database Logo

Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. 1995

S J Chen, and Y F Chen, and Q C Meng, and J Durand, and V S Dicarlo, and S Oparil
Division of Cardiovascular Disease, University of Alabama at Birmingham 35294, USA.

The current study examined the effects of bosentan, an orally active antagonist of endothelin-A and -B receptors, on the development and maintenance of hypoxia (10% O2)-induced pulmonary hypertension and vascular remodeling in the rat. Pretreatment with bosentan (100 mg.kg-1.day-1, 1 gavage/day for 2 days) completely blocked the pulmonary vasoconstrictor response to acute hypoxia. Chronic bosentan treatment (100 mg.kg-1.day-1 po in the food) instituted 48 h before hypoxic exposure prevented the subsequent development of pulmonary hypertension, attenuated the associated right heart hypertrophy, and prevented the remodeling of small (50-100 microns) pulmonary arteries without altering systemic arterial pressure. Institution of bosentan treatment (for 4 wk) after 2 wk of hypoxia produced a significant reversal of established hypoxia-induced pulmonary hypertension (from 36 +/- 1 to 25 +/- 1 mmHg), right heart hypertrophy, and pulmonary vascular remodeling despite continuing hypoxic exposure. These findings support the hypothesis that endogenous endothelin-1 plays a major role in hypoxic pulmonary vasoconstriction and/or hypertension, right heart hypertrophy, and pulmonary vascular remodeling and suggest that endothelin-receptor blockade may be useful in the treatment of hypoxic pulmonary hypertension humans.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D008297 Male Males
D011652 Pulmonary Circulation The circulation of the BLOOD through the LUNGS. Pulmonary Blood Flow,Respiratory Circulation,Circulation, Pulmonary,Circulation, Respiratory,Blood Flow, Pulmonary,Flow, Pulmonary Blood,Pulmonary Blood Flows
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D000077300 Bosentan A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS. 4-t-Butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide,Bosentan Anhydrous,Bosentan Monohydrate,Ro 47-0203,Ro-47-0203,Tracleer,Ro 47 0203,Ro 470203
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000860 Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms. Anoxia,Oxygen Deficiency,Anoxemia,Deficiency, Oxygen,Hypoxemia,Deficiencies, Oxygen,Oxygen Deficiencies
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

S J Chen, and Y F Chen, and Q C Meng, and J Durand, and V S Dicarlo, and S Oparil
Endothelin-B receptor overexpression prevents hypoxic pulmonary hypertension in cirrhotic rats.
December 2005, Chest,
S J Chen, and Y F Chen, and Q C Meng, and J Durand, and V S Dicarlo, and S Oparil
[Endothelin receptor antagonist bosentan. Breakthrough in the treatment of pulmonary hypertension].
December 2004, MMW Fortschritte der Medizin,
S J Chen, and Y F Chen, and Q C Meng, and J Durand, and V S Dicarlo, and S Oparil
The endothelin antagonist bosentan: hemodynamic effects during normoxia and hypoxic pulmonary hypertension in pigs.
October 1996, The Journal of thoracic and cardiovascular surgery,
S J Chen, and Y F Chen, and Q C Meng, and J Durand, and V S Dicarlo, and S Oparil
Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.
November 2014, Journal of cardiovascular pharmacology,
S J Chen, and Y F Chen, and Q C Meng, and J Durand, and V S Dicarlo, and S Oparil
[Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan].
July 2006, Medizinische Monatsschrift fur Pharmazeuten,
S J Chen, and Y F Chen, and Q C Meng, and J Durand, and V S Dicarlo, and S Oparil
Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats.
February 1995, The American journal of physiology,
S J Chen, and Y F Chen, and Q C Meng, and J Durand, and V S Dicarlo, and S Oparil
Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension.
July 2000, Circulation,
S J Chen, and Y F Chen, and Q C Meng, and J Durand, and V S Dicarlo, and S Oparil
Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan.
January 2010, Respiratory physiology & neurobiology,
S J Chen, and Y F Chen, and Q C Meng, and J Durand, and V S Dicarlo, and S Oparil
[Approaches to therapy for pulmonary hypertension: Role of the endothelin receptor antagonist bosentan].
January 2015, Terapevticheskii arkhiv,
S J Chen, and Y F Chen, and Q C Meng, and J Durand, and V S Dicarlo, and S Oparil
The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.
August 2004, European journal of pharmacology,
Copied contents to your clipboard!